Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesOutpatient PPSHCPCS hcpcs-c9309-onasemnogene-abeparvovec-brve-injection-single-treatment
    Ask Trek AI about this page

    HCPCS Level II C9309: Onasemnogene Abeparvovec Injection, Per Treatment

    HCPCS Level II code C9309 represents the billed service for the administration of onasemnogene abeparvovec‑brve as an injection per treatment, a one-time systemic gene therapy infusion used to treat spinal muscular atrophy; service type is gene therapy administration and the typical site of service is an inpatient or ambulatory infusion center or hospital setting where specialized biologic therapies are delivered.

    For related coverage guidance, see recent payer policy updates: Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation, Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation, Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation.

    Customize your policy alerts

    Sign up for hcpcs C9309 policy alerts

    Get alerted when payer policies referencing C9309 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A pediatric patient aged 6 months with genetically confirmed spinal muscular atrophy (SMA) Type 1 presents for a one-time intravenous gene replacement therapy using onasemnogene abeparvovec‑brve. Pre-infusion workflow includes verification of genetic diagnosis, baseline neurologic and respiratory assessment, review of prior immunizations and anti‑AAV9 antibody titer, baseline liver function tests and platelet count, and care coordination with pediatric neurology and infusion pharmacy. On the day of service the patient is admitted to an outpatient infusion center or pediatric hospital ambulatory infusion unit equipped for pediatric resuscitation. The multidisciplinary team includes a pediatric neurologist, pediatric nurse experienced in IV biologic administration, pharmacy staff preparing the weight‑based dose, and a caregiver present for consent and post‑infusion observation. The product, billed as C9309, is administered as a single intravenous infusion over the recommended time; vital signs and liver function are monitored per protocol during and after infusion. Post‑treatment instructions include steroid prophylaxis monitoring, scheduled laboratory follow‑up (liver enzymes, platelets), and neurology clinic follow‑up to assess motor milestones and adverse events.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hourMay be used to report infusion administration time components for initial infusion monitoring if payer accepts alongside the drug HCPCS billing rules.
    96366Each additional hour (list separately in addition to code for primary infusion)Use when infusion monitoring extends beyond the first hour and payer allows time‑based infusion administration coding.
    96372Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscularNot typically used for intravenous gene therapy; may be reported for concurrent IM/SQ injections (e.g., vaccines or steroids) given the same day if separately documented.
    36415Collection of venous blood by venipunctureUsed for baseline and serial laboratory monitoring (liver enzymes, platelet counts) associated with onasemnogene abeparvovec administration.
    94010Breathing capacity test (spirometry)Applicable when baseline or follow‑up respiratory function testing is required for clinical assessment in SMA patients.
    99354Prolonged evaluation and management service in the office or other outpatient setting, face-to-face, first hour (add-on)May be used for extended face‑to‑face time for complex consent, education, or monitoring visit when documentation supports prolonged services and payer accepts add‑on coding.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    47Modifier -47 (“Anesthesia by Surgeon”) is appended to a surgical or procedural CPT code when the surgeon personally provides regional or general anesthesia for the procedure. Use of -47 indicates the…- Use modifier -47 when the surgeon personally provides regional or general anesthesia during the surgical procedure (i.e., the surgeon administers the anesthesia in addition to performing the…
    92Modifier 92 (Alternative Laboratory Platform Testing) is used when laboratory tests are performed with single‑use, disposable, portable kits or transportable instruments. The AMA defines it for tests…- Use modifier 92 when a laboratory test is performed using a single‑use, disposable analytical device or kit (an alternative laboratory platform) that is portable and may be taken to or near the…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RC0000X
    163W00000X
    363L00000X
    251B00000X
    246ZG0701X
    2472R0900X
    2084N0600X
    251T00000X

    Related ICD-10-CM Codes

    18 rows

    ICD-10-CM CodeDescription
    E70.0Classical phenylketonuria
    E78.5Hyperlipidemia, unspecified
    E83.42Hypomagnesemia
    E83.49Other disorders of magnesium metabolism
    E83.9Disorder of mineral metabolism, unspecified
    E88.09Other disorders of plasma-protein metabolism, not elsewhere classified
    E88.9Metabolic disorder, unspecified
    G12.0Infantile spinal muscular atrophy, type I [Werdnig-Hoffman]
    G12.1Other inherited spinal muscular atrophy
    G12.9Spinal muscular atrophy, unspecified

    Showing 1–10 of 18

    Related Payer Policy Updates

    Specialty: Cardiology1 / 3

    10 rows

    PolicyPayerEffective Date
    Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillationpremerabluecrossofwashington2027-02-05
    Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillationpremerabluecrossofwashington2027-02-05
    Percutaneous Left Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillationpremerabluecrossofwashington2027-02-05
    Left Atrial Appendage Occlusion, Closurearkansas_blue_cross_blue_shield2027-02-01
    Percutaneous Left Atrial Appendage Closure - Medical PolicyHealth-New-England2027-02-01
    Transcatheter Mitral Valve Repair Medical PolicyHealth-New-England2027-02-01
    Cardiac Electrophysiological (EP) Studies and Cardiac Ablation of Abnormal Electrical RhythmsCigna2027-01-15
    IvabradineCigna2026-11-15
    Tilt Table TestingCigna2026-11-15
    Cardiac Contractility Modulation for Heart FailureProvidence Health Plan2026-11-01

    Related Codes

    HCPCS-C1713-IMPLANTABLE-ANCHOR-SCREW-BONE-FIXATION

    HCPCS C1713: Anchor/Screw for Bone or Soft Tissue Fixation (Implantable)

    HCPCS-C1714-TRANSLUMINAL-DIRECTIONAL-ATHERECTOMY-CATHETER

    HCPCS C1714: Catheter, transluminal atherectomy, directional

    HCPCS-C1715-BRACHYTHERAPY-NEEDLE

    HCPCS C1715: Brachytherapy Needle

    HCPCS-C1716-BRACHYTHERAPY-GOLD-198-SOURCE

    HCPCS C1716: Brachytherapy Source, Gold-198, Per Source

    HCPCS-C1717-HDR-BRACHYTHERAPY-IRIDIUM-192-SOURCE

    HCPCS C1717: HDR Iridium-192 Brachytherapy Source, Per Source

    HCPCS-C1719-BRACHYTHERAPY-IRIDIUM-192-SOURCE-NON-STRANDED

    HCPCS C1719: Brachytherapy Source, Iridium-192, Non-Stranded

    HCPCS-C1721-IMPLANTABLE-DUAL-CHAMBER-CARDIOVERTER-DEFIBRILLATOR

    HCPCS C1721: Cardioverter-Defibrillator, Dual Chamber (Implantable)

    HCPCS-C1724-ROTATIONAL-TRANSLUMINAL-ATHERECTOMY-CATHETER

    HCPCS Level II C1724: Rotational Transluminal Atherectomy Catheter

    HCPCS-C1725-TRANSLUMINAL-ANGIOPLASTY-CATHETER-NON-LASER

    HCPCS Level II C1725: Transluminal Angioplasty Catheter, Non-Laser

    HCPCS-C1726-NON-VASCULAR-BALLOON-DILATATION-CATHETER

    HCPCS C1726: Catheter, Balloon Dilatation, Non-Vascular

    Showing 1–10 of 603

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.